Title: Platelet Derived Growth Factor Receptor-# as a Non-Invasive Biomarker for Liver
Fibrosis Prediction in Diabetic Non-alcoholic Fatty Liver Disease
Version: 1 Date: 15 Oct 2024
Reviewer:  Panagiotis Tsibouris
Reviewer's report:
MAFLD should replace NAFLD and definitions should be accordingly adapted Abstract A nitch
should be provided about PDGFR# and liver steatosis Methods MAFLD should be excluded in
controls and the way of MAFLD exclusion should be provided Since MASLD excludes alcohol
consumption MetFLD is used for low alcohol consumption, alcohol consumption should be
excluded Definitions of underlined comorbidities should be provided HbsAg is not sufficient
to excluded HBV infection HbcAb and antiHbs are required Could results for F3 and F4 be
presented as well Statistics Non-parametric score utilized should be defined Had authors used
all these tests? In such a case definition of when each test was applied should be provided
Authors should point out why they have selected the cut off points they have used Analysis
in too small samples are dangerous Results significant differences of demographic and clinical
characteristics between patients and controls should be presented in the text and numerical values
as well as p values should be provided  Multivariated analysis in non diabetic patients should
be performed as well unless size of the population is not sufficient to preform it possibly one
analysis for the whole population would be advisable
Title: Platelet Derived Growth Factor Receptor-# as a Non-Invasive Biomarker for Liver
Fibrosis Prediction in Diabetic Non-alcoholic Fatty Liver Disease
Version: 1 Date: 15 Oct 2024
Reviewer:  Panagiotis Tsibouris
Reviewer's report:
MAFLD should replace NAFLD and definitions should be accordingly adapted Abstract A nitch
should be provided about PDGFR# and liver steatosis Methods MAFLD should be excluded in
controls and the way of MAFLD exclusion should be provided Since MASLD excludes alcohol
consumption MetFLD is used for low alcohol consumption, alcohol consumption should be
excluded Definitions of underlined comorbidities should be provided HbsAg is not sufficient
to excluded HBV infection HbcAb and antiHbs are required Could results for F3 and F4 be
presented as well Statistics Non-parametric score utilized should be defined Had authors used
all these tests? In such a case definition of when each test was applied should be provided
Authors should point out why they have selected the cut off points they have used Analysis
in too small samples are dangerous Results significant differences of demographic and clinical
characteristics between patients and controls should be presented in the text and numerical values
as well as p values should be provided  Multivariated analysis in non diabetic patients should
be performed as well unless size of the population is not sufficient to preform it possibly one
analysis for the whole population would be advisable
Please review this paper.
user
Title: Platelet Derived Growth Factor Receptor-# as a Non-Invasive Biomarker for Liver
Fibrosis Prediction in Diabetic Non-alcoholic Fatty Liver Disease
Version: 1 Date: 15 Oct 2024
Reviewer:  Panagiotis Tsibouris
Reviewer's report:
MAFLD should replace NAFLD and definitions should be accordingly adapted Abstract A nitch
should be provided about PDGFR# and liver steatosis Methods MAFLD should be excluded in
controls and the way of MAFLD exclusion should be provided Since MASLD excludes alcohol
consumption MetFLD is used for low alcohol consumption, alcohol consumption should be
excluded Definitions of underlined comorbidities should be provided HbsAg is not sufficient
to excluded HBV infection HbcAb and antiHbs are required Could results for F3 and F4 be
presented as well Statistics Non-parametric score utilized should be defined Had authors used
all these tests? In such a case definition of when each test was applied should be provided
Authors should point out why they have selected the cut off points they have used Analysis
in too small samples are dangerous Results significant differences of demographic and clinical
characteristics between patients and controls should be presented in the text and numerical values
as well as p values should be provided  Multivariated analysis in non diabetic patients should
be performed as well unless size of the population is not sufficient to preform it possibly one
analysis for the whole population would be advisable
assistant